Bluebird bio’s LentiGlobin gene therapy for transfusion-dependent β-thalassemia (TDT) is the only product up for an opinion on potential EU marketing authorization at this month’s meeting of the European Medicines Agency’s key drug evaluation committee, the CHMP, which is taking place for the first time in Amsterdam.
LentiGlobin Hogs The Limelight At CHMP’s First Amsterdam Meeting
An opinion on whether bluebird bio’s transfusion-dependent β-thalassemia gene therapy, LentiGlobin, should be granted an EU marketing authorization is due this week as the EMA’s key scientific committee, the CHMP, meets for the first time in Amsterdam.
